colorectal cancer

Latest Headlines

Latest Headlines

Exact Sciences wins CMS panel vote for Cologuard pricing

Exact Sciences has been working hard to expand reimbursement for its stool-based DNA colorectal cancer test since nabbing Medicare coverage last October, signing on two major private insurers earlier this year. Now the company is celebrating a decision from the Centers for Medicare and Medicaid Services that could lock in Medicare pricing for its test.

WSJ: New devices for rectal cancer surgery reduce need for colostomies

New medical devices for rectal cancer surgeries are helping patients forgo colostomies, shifting more individuals toward a new procedure that requires fewer external adjustments, according to medical experts.

Exact Sciences reveals $175M public offering amid Q2 losses

Exact Sciences raked in $175 million in a public offering to dial up development of its stool-based test for colorectal cancer, giving the company a boost as it counters less-than-stellar second-quarter earnings.

Exact Sciences looks beyond colorectal cancer Dx with extended Mayo Clinic collaboration

Exact Sciences is building on a previous collaboration with Mayo Clinic to develop tests for the gastrointestinal tract, riding high off last year's successes and expanding its offerings beyond colorectal cancer.

Epigenomics scores Chinese marketing approval for innovative colorectal cancer test

Epigenomics won marketing approval in China for its next-generation colorectal cancer test, moving the company forward on its path toward global commercialization for the product and helping it compete in an increasingly competitive playing field.

Exact Sciences nails coveted Medicare coverage for colon cancer DNA test

Exact Sciences now has something that diagnostics companies find increasingly hard to obtain: Medicare coverage, obtained for its new cutting-edge colorectal cancer-screening test.

Belgium's VolitionRx touts positive early results for noninvasive colon cancer Dx

VolitionRx said it will pursue a CE mark application later in 2014 or early 2015, based, in part on initial positive results from a major study involving its noninvasive colorectal cancer diagnostic test panel.

Exact Sciences bags FDA approval and proposed CMS coverage for colorectal cancer screening test

Exact Sciences won FDA approval for its stool-based colorectal cancer diagnostic, charting a regulatory milestone and picking up proposed national coverage for its product along the way.

PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo

Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.

FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug

Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.